Kyorin Pharmaceutical revised its full-year forecast for the fiscal year ending March 2027 to a loss. The factors were the recording of upfront payments associated with the introduction of 2 candidate products as research and development expenses and an increase in its full-year research and development expense forecast.
Kyorin Pharmaceutical announced its financial results on 9 November 2026 and revised down its full-year earnings forecast for the fiscal year ending March 2027. The operating profit/loss forecast was revised from a profit to a loss, worsening the outlook for the current fiscal year. The briefing was held the following day, 10 November.
The main factor behind the downward revision to the full-year forecast was the policy of recording upfront payments associated with the introduction of 2 candidate products as research and development expenses. The full-year research and development expense forecast was raised from ¥9.3 billion to ¥16.2 billion. As a result, the forecast operating loss is expected to widen to ¥4.9 billion.
The company has established the medium-term management plan “Vision 110-Stage2-” (FY2026–FY2029), and the policy of giving the highest priority to expanding its development pipeline through product introductions was reflected in this revision.